Precise insights for better health.

About Us

Democratize Precision Metagenomics

Our mission is to change infectious disease testing with democratized Precision Metagenomics to help characterize diseases with data and actionable insights. Our team comprises some of the foremost experts in microbial genomics, bioinformatics, software engineering, laboratory medicine, infectious disease medicine, and more. We partner with industry leading businesses to bring the highest quality solutions and services to the market.

Uncovering the microbial world

We passionately believe that infectious disease patients should be treated with the same precision that cancer patients receive today. As our population increases, our economies become more global, and we continue over-usage of broad-spectrum antibiotics, infectious diseases are going to continue to spread and become more pernicious. Our clinical practices must evolve with disease to become more precise in our diagnostic and treatment tools. At IDbyDNA, our goal is to accelerate these solutions and uncover the microbial world to reduce infectious disease associated morbidity and mortality.

Leadership Team

Neil Gunn

Chief Executive Officer

Neil is a passionate healthcare innovation leader with over 30 years of experience bringing life-changing biotechnology products to market.

Neil Gunn

Chief Executive Officer

Neil is a passionate healthcare innovation leader with over 30 years of experience bringing life-changing biotechnology products to market. His vision and his focus have always been the development and commercialization of products that make a difference in patients’ lives and deliver value to healthcare providers.

A fierce proponent of an inclusive work culture, Neil is known for honoring the many talents, backgrounds and experiences of co-workers, teams and employees. During his +12 years in multiple positions at Roche Diagnostics, he most recently led their Sequencing business unit, where he grew the business both organically and inorganically by partnering with, growing and integrating multiple startups.

While at Roche Molecular Diagnostics, Neil strategically drove the clinical evidence generation that established cobas HPV as the first molecular test to be approved by the FDA for primary screening of HPV for cervical cancer, improving the clinical outcomes for thousands of women. Prior to Roche, Neil held senior roles in both Europe and the US at Pall Medical Ltd., Novartis Diagnostics, and Gambro BCT. Neil holds a PhD in Marine Microbiology and an MS in Biology from Portsmouth University, UK as well as a BS in Biology from Nottingham Trent University, UK.

Neil spent his childhood years on or in the ocean in the far southwest of England. He became a Nationally qualified Scuba instructor in his early teens and then during his PhD spent time racing and competing in sailing and windsurfing events. To this day he still loves the ocean and in his down time will take hikes on the Northern Californian coast line, claiming that he is now too old to windsurf competitively and that the water is too cold to Scuba dive!

Guochun Liao, PhD, MBA

Founder, Chief Innovation Officer

Guochun Liao is enthusiastic about pushing the boundaries of combining the power of computer sciences with genetics to provide solutions for the biggest challenges in healthcare.

Guochun Liao, PhD, MBA

Founder, Chief Innovation Officer

Guochun Liao is enthusiastic about pushing the boundaries of combining the power of computer sciences with genetics to provide solutions for the biggest challenges in healthcare.

He has 20+ years of experience in leading and managing multi-discipline teams in large pharmaceutical and small biotechnology startup companies. Guochun led the development of innovative computational approaches to solve biological problems and some of his work was featured on the cover of the Journal of Science and Genome Research.

Guochun believes the convergence of technology and biology will redefine the biotechnology industry and accelerate a paradigm shift in medicine. With this vision in mind, he founded IDbyDNA to make NGS metagnomics-based infectious disease testing the standard of care and affordable for everyone.

Before founding IDbyDNA, Guochun was the Vice President of Bioinformatics at Centrillion Biosciences and the Head of Computational Genomics and Research Biostatistics at Roche. During this time, he also served as a consulting professor at Stanford University School of Medicine.

Guochun holds a Bachelor’s degree in Biophysics from the University of Science and Technology of China. He earned a Master’s degree in Computer Science (AI), a PhD in Genetics, and an MBA degree at the University of California, Berkeley. Guochun is also a member of the Alumni Council of Cheung Kong Graduate School of Business.

Outside of work, Guochun loves to hike and cook for his family.

Robert Schlaberg, MD, PhD, MPH

Co-Founder, Chief Medical Officer

Robert Schlaberg is a co-founder and the Chief Medical Officer of IDbyDNA, where he drives the vision of democratized, routine use of genomic technologies for infectious disease detection and surveillance.

Robert Schlaberg, MD, PhD, MPH

Co-Founder, Chief Medical Officer

Robert Schlaberg is a co-founder and the Chief Medical Officer of IDbyDNA, where he drives the vision of democratized, routine use of genomic technologies for infectious disease detection and surveillance. As a co-inventor of IDbyDNA’s core technology, Robert is driven to make Precision Metagenomics accessible, reliable, and intuitive to use for laboratory personnel.

Robert strongly believes that leveraging genomics, computational, and data science approaches will drive a paradigm shift in the management of infectious diseases, dramatically improving both patient care and public health and making a difference in the lives of people around the globe.

Robert received medical degrees from the University of Würzburg (Germany) and a Masters of Public Health from Columbia University, where he also trained as a postdoc in the pathogen discovery lab of W. Ian Lipkin and as a resident and chief resident in Clinical Pathology. Robert completed training as a Medical Microbiologist at ARUP Laboratories, where he also served as a Medical Director in Infectious Diseases for almost 10 years.

Robert is board-certified in Clinical Pathology and Medical Microbiology, served on the Microbiology and Standards Committees of the College of American Pathologists, and on advisory boards for Roche Molecular Diagnostics, Hologic, Illumina, the Joint Research Centre of the European Commission, and the US-FDA.

In his spare time, Robert enjoys the outdoors, especially skiing and mountain biking.

Chris Minunni

VP of Finance & General Counsel

Chris Minunni has spent his career in legal, finance and operations working with technology and life science companies in the San Francisco Bay Area.

Chris Minunni

VP of Finance & General Counsel

Chris Minunni has spent his career in legal, finance and operations working with technology and life science companies in the San Francisco Bay Area. He is motivated by working with companies at the forefront of exciting new technologies that have the potential to change our quality of life.

Before he joined IDbyDNA as Vice President, Finance and General Counsel in 2019, Chris was Vice President of Business Operations and General Counsel at Bracket Computing, a venture-backed enterprise infrastructure and security software company. Previously, he was a corporate attorney at Cooley LLP, where he represented life sciences and technology companies of all stages, and in a wide range of transactions, including venture capital financings, public offerings, and mergers and acquisitions.

Chris holds a JD from Columbia Law School and a BA from Cornell University.

Chris grew up in Buffalo, New York, and calls California home today. He enjoys traveling, playing ice hockey, and is slowly learning how to cook.

Wendy Chang

VP, Head of People

Wendy Chang is passionate about building highly engaged teams where employees can thrive and are able to make a difference in shifting current paradigms in patient care.

Wendy Chang

VP, Head of People

Wendy Chang is passionate about building highly engaged teams where employees can thrive and are able to make a difference in shifting current paradigms in patient care. She has extensive experience as a human resource professional, with over 20 years of life sciences experience at world-class biopharmaceutical companies.

As IDbyDNA’s new Vice President, Head of People, Wendy is responsible for all aspects of the company’s people strategies, including talent acquisition, leadership development and shaping the employee experience, people capabilities and culture.

Previously, Wendy served in multiple leadership roles at Gilead Sciences, most recently as Vice President Human Resources. She has an extensive background in growing and scaling organizations within the Life Sciences industry as they enter “hypergrowth” mode. While at Gilead, she helped the company grow from 1,300 to more than 11,000 employees. Prior to Gilead she worked at Bio-Rad Laboratories.

Wendy is a Global Talent Management Fellow from The Wharton School and holds a Bachelor of Science degree in business administration from the University of California at Riverside.

In her spare time, Wendy enjoys traveling and seeing the world; she has swum with sharks, hiked the Great Wall of China, and snowshoed in the Arctic Circle. She and her family currently reside in the San Francisco Bay Area.

Board of Directors

Guochun Liao, PhD, MBA

Chairman

Guochun Liao is enthusiastic about pushing the boundaries of combining the power of computer sciences with genetics to provide solutions for the biggest challenges in healthcare.

Guochun Liao, PhD, MBA

Chairman

Guochun Liao is enthusiastic about pushing the boundaries of combining the power of computer sciences with genetics to provide solutions for the biggest challenges in healthcare.

He has 20+ years of experience in leading and managing multi-discipline teams in large pharmaceutical and small biotechnology startup companies. Guochun led the development of innovative computational approaches to solve biological problems and some of his work was featured on the cover of the Journal of Science and Genome Research.

Guochun believes the convergence of technology and biology will redefine the biotechnology industry and accelerate a paradigm shift in medicine. With this vision in mind, he founded IDbyDNA to make NGS metagnomics-based infectious disease testing the standard of care and affordable for everyone.

Before founding IDbyDNA, Guochun was the Vice President of Bioinformatics at Centrillion Biosciences and the Head of Computational Genomics and Research Biostatistics at Roche. During this time, he also served as a consulting professor at Stanford University School of Medicine.

Guochun holds a Bachelor’s degree in Biophysics from the University of Science and Technology of China. He earned a Master’s degree in Computer Science (AI), a PhD in Genetics, and an MBA degree at the University of California, Berkeley. Guochun is also a member of the Alumni Council of Cheung Kong Graduate School of Business.

Outside of work, Guochun loves to hike and cook for his family.

Neil Gunn

Chief Executive Officer

Neil is a passionate healthcare innovation leader with over 30 years of experience bringing life-changing biotechnology products to market.

Neil Gunn

Chief Executive Officer

Neil is a passionate healthcare innovation leader with over 30 years of experience bringing life-changing biotechnology products to market. His vision and his focus have always been the development and commercialization of products that make a difference in patients’ lives and deliver value to healthcare providers.

A fierce proponent of an inclusive work culture, Neil is known for honoring the many talents, backgrounds and experiences of co-workers, teams and employees. During his +12 years in multiple positions at Roche Diagnostics, he most recently led their Sequencing business unit, where he grew the business both organically and inorganically by partnering with, growing and integrating multiple startups.

While at Roche Molecular Diagnostics, Neil strategically drove the clinical evidence generation that established cobas HPV as the first molecular test to be approved by the FDA for primary screening of HPV for cervical cancer, improving the clinical outcomes for thousands of women. Prior to Roche, Neil held senior roles in both Europe and the US at Pall Medical Ltd., Novartis Diagnostics, and Gambro BCT. Neil holds a PhD in Marine Microbiology and an MS in Biology from Portsmouth University, UK as well as a BS in Biology from Nottingham Trent University, UK.

Neil spent his childhood years on or in the ocean in the far southwest of England. He became a Nationally qualified Scuba instructor in his early teens and then during his PhD spent time racing and competing in sailing and windsurfing events. To this day he still loves the ocean and in his down time will take hikes on the Northern Californian coast line, claiming that he is now too old to windsurf competitively and that the water is too cold to Scuba dive!

Robert Schlaberg, MD, PhD, MPH

Co-Founder, Chief Medical Officer

Robert Schlaberg is a co-founder and the Chief Medical Officer of IDbyDNA, where he drives the vision of democratized, routine use of genomic technologies for infectious disease detection and surveillance.

Robert Schlaberg, MD, PhD, MPH

Co-Founder, Chief Medical Officer

Robert Schlaberg is a co-founder and the Chief Medical Officer of IDbyDNA, where he drives the vision of democratized, routine use of genomic technologies for infectious disease detection and surveillance. As a co-inventor of IDbyDNA’s core technology, Robert is driven to make Precision Metagenomics accessible, reliable, and intuitive to use for laboratory personnel.

Robert strongly believes that leveraging genomics, computational, and data science approaches will drive a paradigm shift in the management of infectious diseases, dramatically improving both patient care and public health and making a difference in the lives of people around the globe.

Robert received medical degrees from the University of Würzburg (Germany) and a Masters of Public Health from Columbia University, where he also trained as a postdoc in the pathogen discovery lab of W. Ian Lipkin and as a resident and chief resident in Clinical Pathology. Robert completed training as a Medical Microbiologist at ARUP Laboratories, where he also served as a Medical Director in Infectious Diseases for almost 10 years.

Robert is board-certified in Clinical Pathology and Medical Microbiology, served on the Microbiology and Standards Committees of the College of American Pathologists, and on advisory boards for Roche Molecular Diagnostics, Hologic, Illumina, the Joint Research Centre of the European Commission, and the US-FDA.

In his spare time, Robert enjoys the outdoors, especially skiing and mountain biking.

Stuart Peterson, MBA

Senior Partner, ARTIS Ventures

Stuart Peterson is the Founder, President and Senior Partner of ARTIS Ventures, a San Francisco-based Tech & Bio VC firm that led early-stage investments in media giant YouTube and cancer-curing Stemcentrx.

Stuart Peterson, MBA

Senior Partner, ARTIS Ventures

Stuart Peterson is the Founder, President and Senior Partner of ARTIS Ventures, a San Francisco-based Tech & Bio VC firm that led early-stage investments in media giant YouTube and cancer-curing Stemcentrx. Stuart currently serves on the Board of Directors of Locus BioSciences, a gene editing company focused on the creation of powerful antimicrobials, Versa Networks, the leading vendor in the SD-WAN and SD-Security markets, Crediwatch, a data insights-as-a-service platform for business and enterprises, and TAE Life Sciences, which is bringing Boron Neutron Capture Therapy (BNCT) out of research and it into a widely available first-line targeted cancer therapy. He is also a Board Advisor for Cohesity, an infinitely scalable, intelligent enterprise data storage platform, Aether BioSystems, which is delivering chemicals and materials built with biology, Excision BioTherapeutics, a gene editing company focused on curing deadly viruses like HIV, and Fabric Genomics, a genomic interpretation platform. Stuart has been named to the Forbe’s Midas List, CB Insights and New York Times Top 100 Venture Capitalists, and TechCrunch VC of the Year Finalist. He also currently serves on the Board of Trustees for the SFMOMA.

Advisors

Carrie L. Byington, MD

Executive Vice President of UC Health

Carrie L. Byington, MD, is a national leader in pediatrics and infectious disease and serves as Executive Vice President of UC Health, which is comprised of UC’s five academic medical centers, a community-based health system and 18 health professional schools.

Carrie L. Byington, MD

Executive Vice President of UC Health

Carrie L. Byington, MD, is a national leader in pediatrics and infectious disease and serves as Executive Vice President of UC Health, which is comprised of UC’s five academic medical centers, a community-based health system and 18 health professional schools. Prior to joining UC Health, she was Dean of the Texas A&M College of Medicine, Senior Vice President of the Texas A&M University Health Science Center and Vice Chancellor for Health Services at The Texas A&M University System. Her research has focused primarily on bacterial and viral respiratory pathogens in children and has included the development of new diagnostic technology. She has received awards from the Robert Wood Johnson Foundation, the Association of American Medical Colleges, American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the National Institutes of Health. She is an elected member of the National Academy of Inventors and the National Academy of Medicine. Dr. Byington is board certified in both General Pediatrics and Pediatric Infectious Diseases. She received a Bachelor of Science in biology from Texas A&M University and Doctor of Medicine from Baylor College of Medicine.

Adrian Egli, MD, PhD

Professor of Microbiology, University of Basel, Switzerland

Dr. Egli is the Head of the Clinical Bacteriology and Mycology Section at the University Hospital Basel and an Independent Research Group Leader at the Department of Biomedicine, University of Basel. As a physician scientist, he has pioneered the introduction of whole genome sequencing, metagenomics, transcriptomics, and artificial intelligence in clinical microbiology.

Adrian Egli, MD, PhD

Professor of Microbiology, University of Basel, Switzerland

Dr. Egli is the Head of the Clinical Bacteriology and Mycology Section at the University Hospital Basel and an Independent Research Group Leader at the Department of Biomedicine, University of Basel. As a physician scientist, he has pioneered the introduction of whole genome sequencing, metagenomics, transcriptomics, and artificial intelligence in clinical microbiology.

Dr. Egli’s lab has been among the first to routinely perform whole pathogen genome sequencing and developed metagenomics protocols for profiling of multidrug resistant pathogens and rapid diagnostics in critically ill patients. Dr. Egli’s research utilizes a systems biology approach leveraging genomics and data-driven technologies to study host-pathogen interactions, pathogen virulence and transmission. He has authored and co-authored more than 150 scientific articles in leading journals, including Nature, Nature Medicine, Nature Microbiology, and Lancet Infectious Diseases. Dr. Egli coordinates various national initiatives in Switzerland, including the Personalized Swiss Sepsis Study for personalized sepsis management based on continuously collected clinical, laboratory, microbiology, and omics data and the Swiss Pathogen Surveillance Platform.

Tamara Feldblyum

Regulatory, Sequencing & Microbiology Expert — ex-Branch Chief at CDRH/FDA

Dr. Tamara Feldblyum brings broad experience in the field of genomic sequencing and microbiology — combined with nearly two decades of experience leading teams at the FDA’s CDRH Office of In Vitro Diagnostics and Radiological Health as a Branch Chief in the Division of Microbiology Devices.

Tamara Feldblyum

Regulatory, Sequencing & Microbiology Expert — ex-Branch Chief at CDRH/FDA

Dr. Tamara Feldblyum brings broad experience in the field of genomic sequencing and microbiology — combined with nearly two decades of experience leading teams at the FDA’s CDRH Office of In Vitro Diagnostics and Radiological Health as a Branch Chief in the Division of Microbiology Devices.

At the FDA, she was responsible for the regulation of IVDs for many infectious disease classes, including Emergency Use Authorization for over 230 molecular tests for SARS-CoV-2.

Dr. Feldblyum brings a unique combination of expertise – with regulatory insights and sequencing technology experience. Prior to her time at the FDA, she served as the Director of a core sequencing facility at The Institute for Genomic Research (TIGR), where she was responsible for genome library construction, high throughput sequencing, research and development, new technology implementation, and laboratory automation. With nearly 40 years of experience in program and personnel supervision, she has a demonstrated ability to identify and solve novel regulatory and scientific issues where there is little precedent to pull from.

In her new role, Dr. Feldblyum will focus on helping IDbyDNA accelerate the availability of its products in regulated markets.

Gene Myers, PhD

Founding Director, Systems Biology Center, Max-Planck Institute of Molecular Cell Biology and Genetics

Gene Myers is a computer scientist and biotechnologist known for the BLAST search engine and the sequencing of the human genome.

Gene Myers, PhD

Founding Director, Systems Biology Center, Max-Planck Institute of Molecular Cell Biology and Genetics

Gene Myers is a computer scientist and biotechnologist known for the BLAST search engine and the sequencing of the human genome. While at Celera Genomics he advocated whole genome shotgun sequencing and assembled high-quality reconstructions of the fruit fly, human, mouse, and mosquito genomes. In the 80’s Myers invented algorithms for sequence comparison and search including suffix arrays that enable the Burroughs-Wheeler transform used in today’s compact indices for genomic search. In the 90’s he created and perfected the string graph approach to DNA sequencing used at Celera. From 2005 to today, he has focused on the construction of novel microscopes and software for building single cell expression atlases across developmental epochs. Myers has been a professor at U of Arizona and UC Berkeley, a Vice President at Celera Genomics, a Group Leader with Howard Hughes Medical Institute, and currently is a Director of the Max-Planck Society. He is a member of the National Academy of Engineering, USA, the National Academy of Germany, and was awarded the ACM Kannellakis Prize in 2002. Gene received a Bachelor of Science in Mathematics from California Institute of Technology and a PhD in Computer Science from the University of Colorado.

Eddy Rubin, MD, PhD

Chief Scientific Officer, Metabiota

Eddy Rubin is a geneticist and medical researcher whose research includes a series of pioneering studies in the field of human and microbial genomics.

Eddy Rubin, MD, PhD

Chief Scientific Officer, Metabiota

Eddy Rubin is a geneticist and medical researcher whose research includes a series of pioneering studies in the field of human and microbial genomics. Dr. Rubin has published over 250 peer-reviewed manuscripts. While serving as Director of the Department of Energy Joint Genome Institute (JGI) at the Lawrence Berkeley National Laboratory, his team made significant contributions to the Human Genome Project and the sequencing and analysis of thousands of plant, fungal and microbial genomes. In 2016 Dr. Rubin joined Metabiota, a company focused on applying comprehensive risk analytics, as Chief Scientific Officer to help organizations understand and mitigate infectious disease risk. Dr. Rubin received a Bachelor of Arts in Physics from the University of California San Diego and his MD and a PhD in Biophysics from the University of Rochester. He completed his medical residency in pediatrics, and his clinical training in Human Genetics at the University of California San Francisco.

Steven Salzberg, PhD

Director of the Center for Computational Biology, Johns Hopkins University

Steven Salzberg is the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University.

Steven Salzberg, PhD

Director of the Center for Computational Biology, Johns Hopkins University

Steven Salzberg is the Bloomberg Distinguished Professor of Biomedical Engineering, Computer Science, and Biostatistics at Johns Hopkins University. His lab has introduced several pioneering computational systems which are widely used in whole-genome sequencing, RNA sequencing, and metagenomics research including Bowtie, Tophat, Cufflinks, and Kraken. In 2003, he co-founded the first large-scale genomics study of human influenza viruses. In addition to his software, Salzberg has contributed to or led many genome sequencing projects, including the human genome as well as dozens of plant, animal, and microbial genomes. Salzberg is a member of the American Academy of Arts and Sciences and has authored or co-authored over 250 peer-reviewed scientific publications. He also writes a widely-read science column at Forbes. He received a B.A., M.S., and M.Phil. from Yale University, and a Ph.D. in Computer Science from Harvard University.

Karl V. Voelkerding, MD

Chair of the College of American Pathologists' Genomic Medicine Committee

Dr. Karl Voelkerding is one of the world’s leading experts in diagnostic genomics. As part of the College of American Pathologists and the Association for Molecular Pathology he has led the development of guidelines and recommendations for best practices in NGS-based testing.

Karl V. Voelkerding, MD

Chair of the College of American Pathologists' Genomic Medicine Committee

Dr. Karl Voelkerding is one of the world’s leading experts in diagnostic genomics. As part of the College of American Pathologists and the Association for Molecular Pathology he has led the development of guidelines and recommendations for best practices in NGS-based testing.

Dr. Voelkerding is the Past President of the Association for Molecular Pathology (AMP), the Chair of the College of American Pathologists’ (CAP) Genomic Medicine Committee, a senior author of the CAP laboratory accreditation requirements for next generation sequencing-based diagnostics, the recipient of the CAP Distinguished Service Award and the AMP Leadership Award.

Board Certified in Clinical Pathology and Molecular Genetic Pathology, Dr. Voelkerding has more than 30 years of experience in translational and clinical molecular diagnostics with faculty appointments at the University of Wisconsin-Madison and the University of Utah, and as a Medical Director of Genomics at ARUP Laboratories. His research has led to more than 90 publications.

George Weinstock, PhD

Director of Microbial Genomics, Jackson Laboratory for Genomic Medicine

Dr. George Weinstock is a Professor and Director of Microbial Genomics at the Jackson Laboratory for Genomic Medicine where he established a group devoted to genomic studies of infectious diseases and the human microbiome.

George Weinstock, PhD

Director of Microbial Genomics, Jackson Laboratory for Genomic Medicine

Dr. George Weinstock is a Professor and Director of Microbial Genomics at the Jackson Laboratory for Genomic Medicine where he established a group devoted to genomic studies of infectious diseases and the human microbiome. Prior to joining the Jackson Laboratory, Dr. Weinstock served as Associate Director of The Genome Institute at Washington University in St. Louis. In addition he was Co-Director of the Human Genome Sequencing Center (HGSC), and Professor of Molecular and Human Genetics at Baylor College of Medicine. Dr. Weinstock received his B.S. from the University of Michigan and a Ph.D. from the Massachusetts Institute of Technology.

Christopher W. Woods, MD, MPH

Professor of Medicine, Pathology, and Global Health, Duke University, Durham, NC

Dr. Woods serves as Chief of Infectious Diseases at the Durham VA Health System. As an infectious diseases clinician and medical microbiologist, his genomic approach to harnessing the host response for diagnosis of infectious diseases has driven a paradigm shift in the field of infectious disease diagnostics.

Christopher W. Woods, MD, MPH

Professor of Medicine, Pathology, and Global Health, Duke University, Durham, NC

Dr. Woods serves as Chief of Infectious Diseases at the Durham VA Health System. As an infectious diseases clinician and medical microbiologist, his genomic approach to harnessing the host response for diagnosis of infectious diseases has driven a paradigm shift in the field of infectious disease diagnostics.

Dr. Woods’ research focuses on the development of novel diagnostic approaches to infectious disease and the epidemiology of emerging and re-emerging infectious diseases. He has published over 210 peer-reviewed articles and has a particular interest in improving diagnostic capacity in the developing world.

At Duke, Dr. Woods also serves as the Executive Director of the Hubert-Yeargan Center for Global Health, the Associate Director of the Center for Applied Genomics and Precision Medicine, and as a Professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School.

Mark Yandell, PhD

Co-Founder

Mark Yandell is a recognized leader in the field of software development for comparative and functional genomics. He is a Professor of Human Genetics and H.A. & Edna Benning Presidential Endowed Chair at the University of Utah, serves as Director of the Bioinformatics program, and Co-director of the Utah Science Technology and Research Center for Genetic Discovery.

Mark Yandell, PhD

Co-Founder

Mark Yandell is a recognized leader in the field of software development for comparative and functional genomics. He is a Professor of Human Genetics and H.A. & Edna Benning Presidential Endowed Chair at the University of Utah, serves as Director of the Bioinformatics program, and Co-director of the Utah Science Technology and Research Center for Genetic Discovery. In addition to developing essential algorithms for the Human Genome Project, Mark developed software at Celera Genomics used to analyze human, mouse, fruit fly, and mosquito genomes. Mark also serves as Technical Director of the Utah Genome Project, and Associate Director of the University of Utah Program in Personalized Health. Mark holds a PhD in Molecular, Cell & Developmental Biology from The University of Colorado, Boulder and completed his post-doctoral work in Computational Biology at Washington University, St. Louis.

Stephen Young, PhD, D(ABMM)

Medical Director, Research & Clinical Trials, TriCore Reference Laboratories (TRL)

Steve Young is an infectious disease pioneer. During his decades-long career, Dr. Young has provided technical expertise and laboratory operations experience to approximately 40 in-vitro diagnostics device companies and has completed over 200 FDA clinical trials, contributing immeasurable breadth of clinical understanding in the field of microbiological diagnostics.

Stephen Young, PhD, D(ABMM)

Medical Director, Research & Clinical Trials, TriCore Reference Laboratories (TRL)

Steve Young is an infectious disease pioneer. During his decades-long career, Dr. Young has provided technical expertise and laboratory operations experience to approximately 40 in-vitro diagnostics device companies and has completed over 200 FDA clinical trials, contributing immeasurable breadth of clinical understanding in the field of microbiological diagnostics.

Among his many achievements Dr Young helped Roche Molecular Systems, Inc with the first commercial assays for HIV and HCV. His experience with laboratory developed tests (LDT’s) and his work with in-vitro diagnostics device companies has led to the development of many advanced diagnostic tools in use today.

As a faculty member at the University of New Mexico from 1990 to 2015, Dr. Young rose through the academic ranks from Assistant Professor to Professor with responsibility for directing the diagnostic virology laboratory (UNM). Today, his work focuses on research and directing virology and microbiology clinical trials for diagnostic device manufacturers as Medical Director of Research and Clinical Trials at TRL.

Contact us

For all support requests including escalations or troubleshooting support, please contact the IDbyDNA Client Services team via the email form (preferred) or phone number below.

General Response Time: Receipt of new support requests will be acknowledged within 1 business day and additional follow-up or resolution steps will be offered as appropriate.

Phone
Live phone coverage is available Monday-Friday
from 8:00 am to 8:00 pm EST (8 AM – 8 PM EST):
833-Explify (833-397-5439)

After Business Hours:
833-IDbyDNA (833-432-9362)

IDbyDNA Laboratories
675 Arapeen Drive
Suite 100
Salt Lake City, UT 84108

Compliance Hotline
If you have a question or concern about IDbyDNA’s compliance, please click here.

 

  • This field is for validation purposes and should be left unchanged.